U.S. markets closed

Q BioMed Inc. (QBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.9300-0.0150 (-1.59%)
At close: 3:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9450
Open0.9175
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9000 - 0.9400
52 Week Range0.8900 - 1.9500
Volume58,659
Avg. Volume57,474
Market Cap24.294M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-0.4740
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience
    PR Newswire

    Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience

    Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creating access for and selling pharmaceuticals, medical diagnostics and durable medical equipment in the Veterans Administration (VA), Military Health System (MHS) and Indian Healthcare System (IHS). WSI will have 6 Federal Account Managers promoting Strontium89 (Strontium Chloride Sr-89 Injection, USP) within 76 VA and MHS medical centers across the US.

  • Q BioMed Insider to Invest up to $30M in the Company
    PR Newswire

    Q BioMed Insider to Invest up to $30M in the Company

    Q BioMed Inc. (OTCQB: QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial investment of $5,000,000 with an additional $15,000,000 by September 30, 2021 with 50% warrant coverage allowing an additional $10,000,000 investment within 120 days. The Unit Price is set at $1.25 per share, a 31% premium to yesterday's closing price. The investor is expected to ultimately take a seat on the Board.

  • Q BioMed Updates Shareholders
    PR Newswire

    Q BioMed Updates Shareholders

    Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders.